PDL BioPharma (PDLI) Tops Q4 EPS by 12c, Beats on Revenues
Tweet
Share
E-mailGet Alerts PDLI Hot Sheet
Price: $2.47 --0%
Financial Fact:
Interest and other expense: -4.51M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Interest and other expense: -4.51M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Note: EPS may not be comparable
PDL BioPharma (NASDAQ: PDLI) reported Q4 EPS of $0.15, $0.12 better than the analyst estimate of $0.03. Revenue for the quarter came in at $68 million versus the consensus estimate of $45.3 million.
For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- L3Harris CEO steps down amid conduct review, shares drop
- The LGL Group (LGL) Misses Q2 EPS by 8c
- Traws Pharma (TRAW) Tops Q2 EPS by 27c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
